Lawrence Blonde, MD

home / authors / lawrence-blonde-md

Articles

December 16th 2014

Diabetes-Related Quality Measure Attainment: Canagliflozin Versus Sitagliptin Based on a Pooled Analysis of 2 Clinical Trials

Robert A. Bailey, MD Ujjwala Vijapurkar, PhD Gary E. Meininger, MD Marcia F. T. Rupnow, PhD Lawrence Blonde, MD

December 15th 2014

Participating Faculty: Diabetes-Related Quality Measure Attainment: Canagliflozin Versus Sitagliptin Based on a Pooled Analysis of 2 Clinical Trials

Robert A. Bailey, MD Ujjwala Vijapurkar, PhD Gary E. Meininger, MD Marcia F.T. Rupnow, PhD Lawrence Blonde, MD

January 25th 2014

Attainment of Diabetes-Related Quality Measures With Canagliflozin Versus Sitagliptin

Robert A. Bailey, MD C. V. Damaraju, PhD Silas C. Martin, MS Gary E. Meininger, MD Marcia F. T. Rupnow, PhD Lawrence Blonde, MD

April 1st 2007

State of Diabetes Care in the United States

Lawrence Blonde, MD

October 1st 2002

New Directions for Type 2 Diabetes Mellitus Management

Lawrence Blonde, MD

October 1st 2002

Thiazolidinediones in the Treatment of Managed Care Patients with Type 2 Diabetes

Ram Pathak, MD Azar Afaq, MD Lawrence Blonde, MD

Latest Updated Articles

Opdivo packaging | Image credit: Bristol Myers Squibb

Published: May 9th 2024 | Updated: May 21st 2024

FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors

AJMC Q&A with Dr Kristen Whitney | Background image credit: ipopba - stock.adobe.com

Published: August 28th 2024 | Updated: September 8th 2024

Illuminating the Future: Dr Kristen Whitney on What's Next for Dermoscopy

LDL and Lp(a) | Image credit : Amgen

Published: August 4th 2024 | Updated: September 8th 2024

Who Should Have Lp(a) Levels Tested? Experts Take Sides

ASCERTAIN Data: Oral Decitabine-Cedazuridine Outcomes in MDS

Published: September 3rd 2024 | Updated: September 8th 2024

ASCERTAIN Data: Oral Decitabine-Cedazuridine Outcomes in MDS

Luspatercept in Lower Risk MDS: Insights on the COMMANDS Trial

Published: September 3rd 2024 | Updated: September 8th 2024

Luspatercept in Lower Risk MDS: Insights on the COMMANDS Trial

Psoriasis | image credit: pimentos – stock.adobe.com.jpg

Published: August 28th 2024 | Updated: September 8th 2024

TYK2 Inhibitor Zasocitinib Shows High Efficacy, Safety in Moderate to Severe Psoriasis

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions